3-[2-Hydroxy-eth-(Z)-ylidene]-4-methylene-cyclohexanol | 67337-15-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[2-Hydroxy-eth-(Z)-ylidene]-4-methylene-cyclohexanol
• 英文别名: (3Z)-3-(2-hydroxyethylidene)-4-methylidenecyclohexan-1-ol
• CAS: 67337-15-9
• 化学式: C₉H₁₄O₂
• 分子量: 154.209
• InChiKey: CZDJBXLWUULEKA-YWEYNIOJSA-N

物化性质

• 沸点：
  294.1±28.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  [5-Hydroxy-2-methylene-cyclohex-(Z)-ylidene]-acetic acid 生成 3-[2-Hydroxy-eth-(Z)-ylidene]-4-methylene-cyclohexanol
  参考文献：
  名称：

  Lythgoe,B. et al., Journal of the Chemical Society. Perkin transactions I, 1978, p. 387 - 395

  摘要：

  DOI：

文献信息

• NOVEL METHOD
  申请人：Colli Enrico

  公开号：US20100093675A1

  公开（公告）日：2010-04-15

  There is provided a method of prevention of adhesions, eg surgical adhesions, which comprises using a vitamin D compound.

  提供了一种预防粘连的方法，例如手术粘连，其包括使用维生素D化合物。
• NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY
  申请人：Adorini Luciano

  公开号：US20100069339A1

  公开（公告）日：2010-03-18

  There is provided a method of treatment of male sub-fertility by using a vitamin D compound. Compositions and uses are also provided.

  提供了一种使用维生素D化合物治疗男性不育的方法。同时提供了相关的组成物和用途。
• Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol
  申请人：Uskokovic Milan R.

  公开号：US20090137828A1

  公开（公告）日：2009-05-28

  The invention provides a method of producing 20-methyl vitamin D3 compounds of formula (I). The method includes allylic and olefin oxidation, de-carbonylation, carbonyl reduction, fluoride substitution, epoxide deoxygenation, and Wittig-type couplings.

  本发明提供了一种制备式(I)的20-甲基维生素D3化合物的方法。该方法包括烯丙基和烯烃氧化、去羰基化、羰基还原、氟代替、环氧去氧化和威廉逊偶联反应。
• COMPOSITIONS AND METHODS FOR CANCER TREATMENT
  申请人：Swamy Narasimha

  公开号：US20120270839A1

  公开（公告）日：2012-10-25

  Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.
• US8853188B2
  申请人：——

  公开号：US8853188B2

  公开（公告）日：2014-10-07